Literature DB >> 8958600

Neither protein kinase C nor adenylate cyclase are altered in the striatum from subjects with schizophrenia.

K Opeskin1, B Dean, G Pavey, C Hill, N Keks, D Copolov.   

Abstract

Dopamine (DA) D2 receptors which act by modulating second messenger pathways that include protein kinase C (PKC) and adenylate cyclase (AC) have been repeatedly shown to be increased in striatum from subjects with schizophrenia. Therefore it seemed possible that chronic up-regulation of DA-D2 receptors in the schizophrenic brain could result in a change in either of these two proteins. Hence we measured PKC and AC in striatum from 20 schizophrenic subjects and 20 non-schizophrenic subjects by quantitative autoradiography and could show no difference in the density of either PKC (436 +/- 35 vs. 485 +/- 29 fmol/mg tissue equivalents (TE), mean +/- SEM) or AC (77 +/- 9 vs. 80 +/- 7 fmol/mg TE) in the tissue from schizophrenic compared to the non-schizophrenic subjects. Thus, these data do not support the hypothesis that PKC or AC are changed in the schizophrenic brain.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8958600     DOI: 10.1016/s0920-9964(96)00065-5

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  3 in total

Review 1.  Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway.

Authors:  R R Girgis; J A Javitch; J A Lieberman
Journal:  Mol Psychiatry       Date:  2008-04-15       Impact factor: 15.992

2.  Changes in protein kinase C and adenylate cyclase in the temporal lobe from subjects with schizophrenia.

Authors:  B Dean; K Opeskin; G Pavey; C Hill; N Keks
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

3.  Protein and mRNA expression of protein kinase C (PKC) in the postmortem brain of bipolar and schizophrenic subjects.

Authors:  Ghanshyam N Pandey; Hooriyah S Rizavi; Xinguo Ren
Journal:  J Psychiatr Res       Date:  2020-08-09       Impact factor: 4.791

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.